Patents Examined by Svetlana M Ivanova
  • Phenylephrine formulations with improved stability
    Patent number: 10130627
    Abstract: A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 20, 2018
    Assignee: GlaxoSmithKine Consumer Healthcare S.A.
    Inventors: Timothy Dungan, Brian Warrington
  • Method for treatment of hyperglycemia and hyperlipidemia
    Patent number: 10124012
    Abstract: Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin K. Also provided is a method of enhancing protein expression ratio of phospho-5? adenosine monophosphate-activated protein kinase (phospho-AMPK) to total AMPK in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject. Antcin K exerts prominent antidiabetic and antihyperlipidemic effects through regulation of membrane GLUT4, AMPK, Akt PPAR?, FAS, and PPAR? protein expressions and G6Pase, DGAT2, SREBP-1c, aP2, apoCIII, SREBP2, and PPAR? mRNA expressions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 13, 2018
    Inventor: Chun-Ching Shih
  • CHG-compatible composition and method
    Patent number: 10124067
    Abstract: A composition for soothing irritation that does not diminish the efficacy of a topical antiseptic is disclosed. The composition comprises an emollient, an emulsifier, and a film-forming agent. Also, a method of soothing irritation without diminishing the efficacy of a topical antiseptic product comprises the steps of providing the topical antiseptic product comprising a cationic antiseptic agent, providing the composition, applying the topical antiseptic product to a target area on skin of a patient to coat the target area with the cationic antiseptic agent, and applying the composition to the coated target area.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: November 13, 2018
    Assignee: Sage Products, LLC
    Inventors: Jodi M. Balbinot, Arthur C. W. Georgalas
  • Formulations and methods for lyophilization and lyophilates provided thereby
    Patent number: 10117834
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 6, 2018
    Assignee: BIOGEN CHESAPEAKE LLC
    Inventor: Sven Jacobson
  • Compositions and methods for preserving donated blood
    Patent number: 10117428
    Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 6, 2018
    Assignee: Rythrx Therapeutics, LLC
    Inventor: Narayanan Surendran
  • Compositions and methods for treating diseases of the nail
    Patent number: 10105444
    Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, which composition has a surface tension of 40 dynes/cm or less and has continuing spreadability, and which composition is effective in treating a disorder of the nail or nail bed.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 23, 2018
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Gareth Winckle, Gregory T. Fieldson
  • Composition and methods for modulating a kinase cascade
    Patent number: 10106505
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: October 23, 2018
    Assignee: Athenex, Inc.
    Inventor: David G. Hangauer, Jr.
  • Methods and compositions for treating diabetes, metabolic syndrome and other conditions
    Patent number: 10098877
    Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: October 16, 2018
    Assignee: Strongbridge Ireland Limited
    Inventor: Per Marin
  • Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
    Patent number: 10092550
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 9, 2018
    Assignee: Ions Pharmaceutical S.à r.l.
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Systems and methods for treating bacterial infection
    Patent number: 10080751
    Abstract: Therapeutic methods, kits, dosing regimens and uses of a medicament comprising iclaprim are provided, for example, for the treatment of bacterial infection. The administration of iclaprim in a fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The bacterial infection treated may be caused, or related to, drug-resistant bacteria including S. pneumoniae, H. influenzae, S. aureus, K. pneumoniae and M. catarrhalis. The bacterial infection may manifest as a skin and skin structure infection, pneumonia, asthma, emphysema and/or other adverse pulmonary conditions.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: September 25, 2018
    Assignee: Motif Biosciences Inc.
    Inventor: David Huang
  • Systems and methods for treating bacterial infection
    Patent number: 10076522
    Abstract: Therapeutic methods, kits, dosing regimens and uses as medicament are provided, for example, for the treatment of bacterial infection. The therapeutic methods can comprise intravenously administering to a subject who has a bacterial infection a pharmaceutical composition comprising a fixed amount of iclaprim. The administration of the fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The pharmaceutical composition can be infused into the subject about 1 to about 3 times a day daily over a time period of about 0.75 hours to about 4 hours.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: September 18, 2018
    Assignee: Motif Biosciences Inc.
    Inventors: David Huang, Keith A. Bostian, William G. Kramer
  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 10064846
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: September 4, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Administration regime for nitrocatechols
    Patent number: 10065944
    Abstract: A compound of formula (I) where R1, R2, X, Y, n, m, R3, R4, R5, R6 and R7 are as defined herein, for use in the prophylaxis or treatment of a central and peripheral nervous system disorder, wherein the compound of formula (I) is administered prior to sleep, before bedtime or at bedtime.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: September 4, 2018
    Assignee: BIAL-PORTELA & CA, S.A.
    Inventors: Patricio Manuel Vieira Araujo Soares Da Silva, Teresa Lucia Silva Pereira Nunes, Lyndon Christopher Wright, Pedro Nuno Leal Palma, David Alexander Learmonth
  • Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis
    Patent number: 10058558
    Abstract: The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: August 28, 2018
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Soon Im Lee, Yeon Jung Song, Min Jae Shin, Kook Hwan Oh, Kyung Don Ju, Eun Kyoung Shin, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Min Jeong Kim, Hye Soun Eum
  • Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
    Patent number: 10059708
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: August 28, 2018
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith
  • Preservative free bimatoprost and timolol solutions
    Patent number: 10058560
    Abstract: The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intraocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: August 28, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly, Jie Shen, Marina Bejanian, Rhett Schiffman
  • Formulations of bendamustine
    Patent number: 10052385
    Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 21, 2018
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Srikanth Sundaram
  • Dosing regimen for sedation with CNS 7056 (remimazolam)
    Patent number: 10052334
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 21, 2018
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Coumarin based Hsp90 inhibitors with urea and ether substituents
    Patent number: 10030006
    Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 24, 2018
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Huiping Zhao
  • Oxidized lipids and treatment or prevention of fibrosis
    Patent number: 10022388
    Abstract: The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: July 17, 2018
    Assignee: Vascular Biogenics Ltd.
    Inventors: Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart